Skip to main content

Table 3 Hemodynamic parameters

From: Oral treatment with a zinc complex of acetylsalicylic acid prevents diabetic cardiomyopathy in a rat model of type-2 diabetes: activation of the Akt pathway

Parameters ZL
(n = 7–10)
ZDF
(n = 7)
ZDF + Zn(ASA)2
(n = 6)
ZL + Zn(ASA)2
(n = 9)
Basic hemodynamic data
 Heart rate (beats/min) 366 ± 12 346 ± 14 355 ± 12 373 ± 13
 SBP (mmHg) 138 ± 5 151 ± 6 153 ± 6 141 ± 7
 DBP (mmHg) 106 ± 3 108 ± 7 110 ± 5 107 ± 6
 MAP (mmHg) 112 ± 4 122 ± 7 124 ± 5 118 ± 6
 CO (ml/min) 31.0 ± 2.8 35.6 ± 5.3 35.6 ± 2.3 30.2 ± 4.1
Systolic function
 Stroke volume (µl) 85 ± 7 93 ± 13 100 ± 5 81 ± 11
 Stroke work (mmHg*ml) 8.56 ± 0.88 10.71 ± 1.28 11.25 ± 0.78 7.86 ± 1.09
 LVESP (mmHg) 131 ± 5 131 ± 6 128 ± 7 133 ± 7
 Ees (mmHg/µl) 1.13 ± 0.13 0.75 ± 0.11 0.85 ± 0.06 1.18 ± 0.24
Diastolic function
 Tau (Weiss) (ms) 9.8 ± 0.3 10.3 ± 0.7 10.2 ± 0.3 9.9 ± 0.4
  1. In vivo cardiac catheterization findings of ZDF (Zucker diabetic fatty) and Zucker lean (nondiabetic) rats after 24 days of treatment with either vehicle or Zn(ASA)2. Values are mean ± SEM, * P < 0.05 vs. ZL, $ P < 0.05 vs. ZL + Zn(ASA)2
  2. Zn(ASA) 2 indicates a zinc complex of acetylsalicylic acid, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean blood pressure, CO cardiac output, LVESP left ventricular end systolic pressure, E es the slope Ees of the left ventricular end-systolic pressure–volume relationship, Tau time constant of left ventricular decay, n number of animals analysed